After Market

The state of drug development in Australia: a case study


Listen Later

Amplia Therapeutics Ltd CEO and managing director Dr Chris Burns has had a long career in drug development, including discovering only the second Australian drug to receive US FDA approval. He has plenty of advice to share for Australian-based researchers and domestically developed biotech assets. Proactive's Susanna Nelson chats to him about the current state of clinical research and commercial drug development in Australia.
...more
View all episodesView all episodes
Download on the App Store

After MarketBy Proactive Australia